COMMUNIQUÉS West-GlobeNewswire

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
12/02/2026
2025 total revenue of $673 million, Crysvita ® revenue of $481 million and Dojolvi ® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a [...]
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
12/02/2026
WARSAW, Ind., Feb. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
12/02/2026
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of [...]
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/02/2026
LEXINGTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
Amwell® Announces Results for Fourth Quarter and Full Year 2025
12/02/2026
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the fourth [...]
Celcuity Appoints Charles Romp to its Board of Directors
12/02/2026
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles ( [...]
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report
12/02/2026
NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period and full year ended [...]
BBOT to Participate in Upcoming Investor Healthcare Conferences
12/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
12/02/2026
AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31 [...]
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results
12/02/2026
MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results: Q4 2025 Q4 [...]
Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026
12/02/2026
PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
12/02/2026
VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company [...]
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
12/02/2026
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the [...]
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
12/02/2026
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
12/02/2026
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
12/02/2026
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, [...]
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
12/02/2026
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common stock (the “Offering”). [...]
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
12/02/2026
BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and [...]
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
12/02/2026
ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]

Pages